相关实验视频

Updated: Jul 1, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

一个集成的CSF-血清生物标志物模型用于预测阿尔茨海默病的临床进展

Xichun Wang¹, Ye Tang², Qiwen Zhang³

¹Department of Neurology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.

Frontiers in aging neuroscience

|February 12, 2026

概括

结合脑脊液 (CSF) pTau181与血清白蛋白与血球蛋白 (A/G) 比率和血小板与淋巴细胞比率 (PLR) 的结合,可以准确预测阿尔茨海默病 (AD) 的进展. 这种综合生物标志物方法提高了AD风险分层的诊断准确性.

科学领域:

神经科学是一个神经科学.
生物标志物发现发现
医学诊断医学诊断医学诊断

背景情况:

早期和准确的阿尔茨海默氏病 (AD) 鉴定是一个重大的临床挑战.
将外周血液生物标志物与脑脊液 (CSF) 测量相结合,可以提高AD的诊断准确性和风险分层.

研究的目的:

开发和验证阿尔茨海默病 (AD) 进展的预测模型,使用CSF和外周血液生物标志物的组合.
在培训,测试和外部验证队伍中评估综合生物标志物模型的诊断性能.

主要方法:

91名参与者的队列接受了CSF和血清测试,随机分为训练 (n=63) 和测试 (n=28) 组.
外部验证使用了来自ADNI数据库的数据 (n=639).
使用后勤回归开发了一个结合CSF pTau181,血清A/G比率和PLR的预测模型,并使用AUC,校准曲线和DCA进行评估.

主要成果:

整合CSF pTau181,A/G比率和PLR的最终模型实现了强大的歧视,AUC为0.92 (培训),0.86 (测试) 和0.83 (外部验证).
该模型显示出优异的校准 (MAE=0.039),在测试组中具有83%的灵敏度和86%的特异性.
更高的A/G比率与AD进展风险降低相关,而更高的PLR表明风险增加.

结论:

结合的CSF-外周血液生物标志物模型显示了强大的预测性能AD进展.
这种综合方法将中央病理与外围营养和炎症标志物联系在一起,有助于临床风险分层.
建议进一步进行大规模的前性验证,以确认这个生物标志物板的实用性.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.专辑蛋白与血球蛋白的比率.这个名字是名ogramogram.第181章没有了血小板与淋巴细胞的比率.

更多相关视频

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...